Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Rises By 88.0%

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the target of a significant increase in short interest during the month of December. As of December 15th, there was short interest totaling 2,177 shares, an increase of 88.0% from the November 30th total of 1,158 shares. Based on an average daily volume of 82,197 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.2% of the company’s stock are short sold. Approximately 0.2% of the company’s stock are short sold. Based on an average daily volume of 82,197 shares, the days-to-cover ratio is presently 0.0 days.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Squarepoint Ops LLC increased its stake in shares of Bolt Biotherapeutics by 19.8% during the third quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock worth $79,000 after buying an additional 2,448 shares during the period. Shay Capital LLC purchased a new stake in shares of Bolt Biotherapeutics in the 3rd quarter valued at approximately $85,000. Finally, Susquehanna International Group LLP acquired a new stake in shares of Bolt Biotherapeutics in the 3rd quarter valued at $89,000. Institutional investors and hedge funds own 86.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on BOLT shares. Zacks Research downgraded Bolt Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Wednesday, October 8th. Finally, HC Wainwright set a $7.00 price target on Bolt Biotherapeutics and gave the stock a “buy” rating in a research report on Monday, October 20th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Bolt Biotherapeutics has an average rating of “Hold” and a consensus target price of $34.00.

Bolt Biotherapeutics Price Performance

Shares of BOLT stock traded up $0.13 on Friday, reaching $5.33. 41,977 shares of the company were exchanged, compared to its average volume of 58,421. The company has a market cap of $10.23 million, a price-to-earnings ratio of -0.24 and a beta of 0.93. The business has a 50-day moving average price of $5.25 and a 200 day moving average price of $5.50. Bolt Biotherapeutics has a 1 year low of $4.41 and a 1 year high of $12.60. The company has a debt-to-equity ratio of 0.65, a quick ratio of 3.57 and a current ratio of 3.57.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($3.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($5.07) by $1.35. The business had revenue of $2.17 million for the quarter, compared to analysts’ expectations of $0.82 million. Equities research analysts forecast that Bolt Biotherapeutics will post -1.61 earnings per share for the current fiscal year.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.